Value of molecular imaging in diagnosis and differential diagnosis of cerebral amyloid angiopathy

doi:10.12047/j.cjap.5972.2020.095

Abstract

ZHANG Shan-chun, SHANG Yan-chang, LI Ke, SUN Xuan, ZHOU Bo, FU Li-ping, XU Bai-xuan, JIA Jian-jun, WANG Zhen-fu, WU Wei-ping. Value of molecular imaging in diagnosis and differential diagnosis of cerebral amyloid angiopathy[J]. CJAP, 2020, 36(5): 448-451.

References

[1] Charidimou A, Boulouis G, Gurol ME, et al. Emerging concepts in sporadic cerebral amyloid angiopathy[J]. Brain, 2017, 140(7): 1829-1850.
[2] DeSimone CV, Graff-Radford J, El-Harasis MA, et al. Cerebral amyloid angiopathy: diagnosis, clinical implications, and management strategies in atrial fibrillation[J]. J Am Coll Cardiol, 2017, 70(9): 1173-1182.
[3] Cannistraro RJ, Meschia JF, et al. The clinical dilemma of anticoagulation use in patients with cerebral amyloid angiopathy and atrial fibrillation[J]. Curr Cardiol Rep, 2018, 20(11): 106.
[4] Charidimou A, Frosch MP, Salman RA, et al. Advancing diagnostic criteria for sporadic cerebral amyloid angiopathy: Study protocol for a multicenter MRI-pathology validation of Boston criteria v2.0[J]. Int J Stroke, 2019: 1747493019855888.
[5] Bensaidane MR, Beauregard JM, Poulin S, et al. Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers[J]. J Alzheimers Dis, 2016, 52(4): 1251-1262.
[6] Farid K, Hong YT, Aigbirhio FI, et al. Early-phase 11C-PiB PET in amyloid angiopathy-related symptomatic cerebral hemorrhage: potential diagnostic value[J]? PLoS One, 2015, 10(10): e0139926.
[7] Farid K, Charidimou A, Baron JC, et al. Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update [J]. NeuroImage-Clin, 2017, 15: 247-263.
[8] Folstein MF, Folstein SE, Mchugh PR, et al. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res, 1975, 12(3): 189-198.
[9] Baron JC, Farid K, Dolan E, et al. Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage[J]. J Cerebr blood F Met, 2014, 34(5): 753-758.
[10]Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy[J]. Ann Neurol, 2007. 62(3):229-234.
[11]Ly JV, Donnan GA, Villemagne VL, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage[J]. Neurology, 2010, 74(6): 487-493.
[12]Seo SW, Ayakta N, Grinberg LT, et al. Regional correlations between [(11)C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort[J]. NeuroImage Clin, 2017, 13: 130-137.
[13]Gurol ME, PhD AVM, Christopher Gidicsin BA, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: A positron emission tomography/magnetic resonance imaging study[J]. Ann Neurol, 2013, 73(4): 529.
[14]Lee SH, Ryu WS, Roh JK, et al. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage[J]. Neurology, 2009, 72(2): 171-176.
[15]Goos JD, Wm VDF, Knol DL, et al. Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging[J]. Stroke, 2011, 42(7): 1894-1900.
[16]Dierksen GA, Skehan ME, Khan MA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy[J]. Ann Neurol, 2010, 68(4): 545-548.
[17]Gurol ME, Dierksen G, Betensky R, et al. Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy[J]. Neurology, 2012, 79(4): 320-326.
[18]Johnson KA, Gregas M, Becker JA. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy[J]. Ann Neurol, 2007, 62(3): 229-34.
[19]van Veluw SJ, Kuijf HJ, Charidimou A, et al. Reduced vascular amyloid burden at microhemorrhage sites in cerebral amyloid angiopathy[J]. Acta Neuropathol, 2016: 1-7.